Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| regulatory T cell | 6 studies | 17% ± 2% | |
| CD16-positive, CD56-dim natural killer cell, human | 5 studies | 18% ± 1% | |
| CD8-positive, alpha-beta T cell | 5 studies | 20% ± 5% | |
| classical monocyte | 5 studies | 28% ± 10% | |
| epithelial cell | 5 studies | 31% ± 10% | |
| natural killer cell | 5 studies | 20% ± 3% | |
| B cell | 4 studies | 22% ± 3% | |
| ciliated cell | 4 studies | 24% ± 5% | |
| CD4-positive, alpha-beta T cell | 3 studies | 21% ± 6% | |
| conventional dendritic cell | 3 studies | 34% ± 12% | |
| effector memory CD8-positive, alpha-beta T cell | 3 studies | 22% ± 4% | |
| hematopoietic precursor cell | 3 studies | 23% ± 4% | |
| non-classical monocyte | 3 studies | 32% ± 7% | |
| endothelial cell | 3 studies | 25% ± 6% | |
| dendritic cell | 3 studies | 37% ± 13% | |
| plasmacytoid dendritic cell | 3 studies | 24% ± 3% | |
| gamma-delta T cell | 3 studies | 25% ± 13% | |
| memory B cell | 3 studies | 16% ± 0% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| esophagus | 100% | 1745.77 | 1445 / 1445 | 100% | 52.62 | 183 / 183 |
| liver | 100% | 1053.38 | 226 / 226 | 100% | 52.92 | 406 / 406 |
| ovary | 100% | 1335.95 | 180 / 180 | 100% | 38.96 | 430 / 430 |
| pancreas | 100% | 1538.66 | 328 / 328 | 100% | 68.76 | 178 / 178 |
| skin | 100% | 2590.03 | 1809 / 1809 | 100% | 82.00 | 472 / 472 |
| thymus | 100% | 2027.59 | 653 / 653 | 100% | 69.52 | 605 / 605 |
| uterus | 100% | 1554.75 | 170 / 170 | 100% | 96.19 | 459 / 459 |
| brain | 100% | 1042.28 | 2632 / 2642 | 100% | 55.31 | 705 / 705 |
| intestine | 100% | 1859.50 | 966 / 966 | 100% | 69.29 | 525 / 527 |
| adrenal gland | 100% | 1802.92 | 258 / 258 | 100% | 43.40 | 229 / 230 |
| kidney | 100% | 2059.35 | 89 / 89 | 100% | 48.75 | 897 / 901 |
| breast | 100% | 1930.81 | 459 / 459 | 99% | 76.51 | 1111 / 1118 |
| lung | 100% | 1850.48 | 578 / 578 | 99% | 68.62 | 1147 / 1155 |
| prostate | 100% | 2521.01 | 245 / 245 | 99% | 67.84 | 498 / 502 |
| stomach | 100% | 1660.22 | 359 / 359 | 99% | 58.12 | 283 / 286 |
| bladder | 100% | 1754.67 | 21 / 21 | 99% | 89.09 | 498 / 504 |
| adipose | 100% | 1835.10 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 100% | 93.72 | 80 / 80 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 142.68 | 29 / 29 |
| spleen | 100% | 2734.57 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 110.00 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 116.77 | 1 / 1 |
| blood vessel | 100% | 1436.51 | 1333 / 1335 | 0% | 0 | 0 / 0 |
| peripheral blood | 99% | 2555.59 | 924 / 929 | 0% | 0 | 0 / 0 |
| muscle | 99% | 1498.51 | 797 / 803 | 0% | 0 | 0 / 0 |
| heart | 98% | 1011.82 | 848 / 861 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0006915 | Biological process | apoptotic process |
| GO_0090312 | Biological process | positive regulation of protein deacetylation |
| GO_0030336 | Biological process | negative regulation of cell migration |
| GO_1902455 | Biological process | negative regulation of stem cell population maintenance |
| GO_1902459 | Biological process | positive regulation of stem cell population maintenance |
| GO_0042981 | Biological process | regulation of apoptotic process |
| GO_2000210 | Biological process | positive regulation of anoikis |
| GO_0030512 | Biological process | negative regulation of transforming growth factor beta receptor signaling pathway |
| GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
| GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
| GO_0032088 | Biological process | negative regulation of NF-kappaB transcription factor activity |
| GO_0070822 | Cellular component | Sin3-type complex |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0005634 | Cellular component | nucleus |
| GO_0051059 | Molecular function | NF-kappaB binding |
| GO_0005515 | Molecular function | protein binding |
| GO_0042826 | Molecular function | histone deacetylase binding |
| Gene name | BRMS1 |
| Protein name | BRMS1 transcriptional repressor and anoikis regulator (Breast cancer metastasis suppressor 1, isoform CRA_c) BRMS1 transcriptional repressor and anoikis regulator Breast cancer metastasis-suppressor 1 |
| Synonyms | hCG_20309 |
| Description | FUNCTION: Transcriptional repressor. Down-regulates transcription activation by NF-kappa-B by promoting the deacetylation of RELA at 'Lys-310'. Promotes HDAC1 binding to promoter regions. Down-regulates expression of anti-apoptotic genes that are controlled by NF-kappa-B. Promotes apoptosis in cells that have inadequate adherence to a substrate, a process called anoikis, and may thereby inhibit metastasis. May be a mediator of metastasis suppression in breast carcinoma. . |
| Accessions | ENST00000524699.5 E9PPD1 H0YCF7 Q9HCU9 G5E9I4 ENST00000527375.5 E9PJF5 ENST00000359957.8 ENST00000530756.1 ENST00000425825.6 |